Dr. Karnes' primary area of research interest is cardiovascular pharmacogenomics, specifically investigating the utility of genetic polymorphisms to predict toxicities of cardiovascular drugs. He employs a translational approach to investigate pharmacogenomic associations using observational studies, functional genomics techniques, and eventually prospective clinical trials. His ultimate career goal is to facilitate personalized cardiovascular medicine and genotype-guided prescribing to avoid serious cardiovascular drug toxicities. Dr. Karnes is an author on 42 peer-reviewed manuscripts and 36 abstracts presented at national and international meetings. He is active in multiple professional societies including the AMERICAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS, the AMERICAN HEART ASSOCIATION, and the AMERICAN COLLEGE OF CLINICAL PHARMACY. He has received funding for his research from the NATIONAL INSTITUTES OF HEALTH, the American Heart Association, the FLINN FOUNDATION, and the American College of Clinical Pharmacy.